Edoxaban tosilate: Direct factor Xa inhibitor prevention of post-operative venous thromboembolism treatment of atrial fibrillation

Drugs of the Future

Volumn 34, Issue 11, 2009, Pages 861-872

  Escolar, G ^a   Diaz Ricart M ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A INHIBITOR; DALTEPARIN; DU 176B; EDOXABAN TOSILATE; FONDAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; MELAGATRAN; PLACEBO; SERINE PROTEINASE; UNCLASSIFIED DRUG; WARFARIN;

ARTERIAL WALL THICKNESS; ARTERY THROMBOSIS; BLEEDING; CLINICAL STUDY; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; ELECTIVE SURGERY; ENZYME ACTIVITY; EXPERIMENTAL MODEL; HEART ATRIUM FIBRILLATION; HIP ARTHROPLASTY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; POSTOPERATIVE PERIOD; PREDICTION; REVIEW; SPECIES; STROKE; THROMBOSIS PREVENTION; TOTAL KNEE REPLACEMENT; URINARY EXCRETION; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

EID: 84930537624     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2009.034.11.1445298     Document Type: Review

References (47)

1. Nagasawa, Sato, K., Yagi, T., H., Kitani, Y. (Daiichi Sankyo Co., Ltd.). Process for producing thiazole derivative. CA 2545730, EP 1683800, US 7547786, US 2007135476, US 2009192313.
2. Ohta, T., Komoyira, S., Yoshimo, T. et al. (Daiichi Sankyo Co., Ltd.). Diamine derivatives. CA 2451605, CA 2456841, EP 1405852, EP 1415992, JP 2008143905, US 2005020645, US 2005119486, US 2005245565, US 2008015215, US 2009270446, US 7342014, US 7365205, WO 2003000657, WO 2003000680, WO 2003016302.
3. Ohta, T., Komoriya, S., Yoshino, T. et al. (Daiichi Sankyo Co., Ltd.). Diamine derivatives. CA 2511493, EP 1577301, JP 2007070369, JP 2008138011, US 2006252837, US 2009281074, US 7576135, WO 2004058715.
4. Sato, K., Kawanami, K., Yagi, T. (Daiichi Sankyo Co., Ltd.). Optically active diamine derivative and process for producing the same. EP 1925611, JP 2007106759, US 2009105491, WO 2007032498.
5. Schwartz, H.M., Wu, W.-S., Marr, P.W., Jones, J.B. Predicting the enantiomeric selectivity of chymotrypsin. Homologous series of ester substances. J Am Chem Soc 1978, 100(16): 5199-5203
6. Noguchi, S., Koyama, T. (Daiichi Sankyo Co., Ltd.). Process for production of diamine derivative. WO 2008156159.
7. Heit, J.A., Cohen, A. T., Anderson, F. A., Jr., on Behalf of the VTE Impact Assessment Group. Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the US. 47th Am Soc Hematol (Dec 10-13, Georgia) 2005, Abst 910.
8. Fowkes, F.J., Price, J. F., Fowkes, F. G. Incidence of diagnosed deep vein thrombosis in the general population: Systematic review. Eur J Vasc Endovasc Surg 2003, 25(1): 1-5.
9. Geerts, W.H., Bergqvist, D., Pineo, G. F. et al. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 2008, 133(6 suppl): 381S-453S.
10. Hughes, M., Lip, G. Y. Stroke and thromboembolism in atrial fibrillation: A systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost 2008, 99(2): 295-304.
11. Turpie, A.G. Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Arterioscler Thromb Vasc Biol 2007, 27(6): 1238-1247
12. Kubitza, D., Becka, M., Voith, B., Zuehlsdorf, M., Wensing, G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 2005, 78(4): 412-421 (Pubitemid 41393676)
13. Hara, T., Yokoyama, A., Ishihara, H., Yokoyama, Y., Nagahara, T., Iwamoto, M. DX-9065a, a new synthetic, potent anticoagulant and selective inhibitor for factor Xa. Thromb Haemost 1994, 71(3): 314-319
14. Morishima, Y., Tanabe, K., Terada, Y., Hara, T., Kunitada, S. Antithrombotic and hemorrhagic effects of DX-906Sa, a direct and selective factor Xa inhibitor: Comparison with a direct thrombin Inhibitor and antithrombin III-dependent anticoagulants. Thromb Haemost 1997, 78(5): 1366-1371 (Pubitemid 27491312)
15. Shimbo, D., Osende, J., Chen, J. et al. Antithrombotic effects of DX-9065a, a direct factor Xa inhibitor: A comparative study in humans versus low molecular weight heparin. Thromb Haemost 2002, 88(5): 733-738 (Pubitemid 35345328)
16. Alexander, J.H., Yang, H., Becker, R. C. et al. First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS Trial. J Thromb Haemost 2005, 3(3): 439-447 (Pubitemid 41632866)
17. Fujii, Y., Takahashi, M., Morita, H., Kikuchi, H., Aramaki, Y., Amidon, G.L. Characteristics of gastrointestinal absorption of DX-9065a, a new synthetic anticoagulant. Drug Metab Pharmacokinet 2007, 22(1): 26-32.
18. Liang, A.M., Light, D. R., Kochanny, M. et al. Discovery and characterization of a potent and selective non-amidine inhibitor of human factor Xa. Biochem Pharmacol 2003, 65(9): 1407-1418 (Pubitemid 36555828)
19. Haginoya, N., Kobayashi, S., Komoriya, S., Yoshino, T., Nagata, T., Hirokawa, Y., Nagahara, T. Design, synthesis, and biological activity of non-amidine factor Xa inhibitors containing pyridine N-oxide and 2-carbamoylthiazole units. Bioorg Med Chem 2004, 12(21): 5579-5586 (Pubitemid 39304057)
20. Haginoya, N., Kobayashi, S., Komoriya, S. et al. Synthesis and conformational analysis of a non-amidine factor Xa inhibitor that incorporates 5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine as S4 binding element. J Med Chem 2004, 47(21): 5167-5182
21. Nagata, T., Yoshino, T., Haginoya, N. et al. Discovery of N-[(1R,2S,5S)-2-{[(5-chloroindol-2-yl)carbonyl]amino}-5-(dimethylcarbamoyl) cyclohexyl]-5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamide hydrochloride: A novel, potent and orally active direct inhibitor of factor Xa. Bioorg Med Chem 2009, 17(3): 1193-1206
22. Furugohri, T., Isobe, K., Honda, Y. et al. DU-176b, a potent and orally active factor Xa inhibitor: In vitro and in vivo pharmacological profiles. J Thromb Haemost 2008, 6(9): 1542-1549
23. Furugohri, T., Kamisato-Matsumoto, C., Morishima, Y., Shibano, T. Inhibition of thrombin generation in human plasma by the oral direct factor Xa inhibitor DU-176b in vitro. J Thromb Haemost 2009, 7(2): Abst PP-TH-195.
24. Fukuda, T., Honda, Y., Matsumoto, C. et al. Impact of antithrombin deficiency on efficacies of DU-176b, a novel orally active direct factor Xa inhibitor, and antithrombin dependent anticoagulants, fondaparinux and heparin. 47th Am Soc Hematol (Dec 10-13, Georgia) 2005, Abst 1874.
25. Morishima, Y., Furugohri, T., Honda, Y. et al. Antithrombotic properties of DU-176b, a novel orally active factor Xa inhibitor: Inhibition of both arterial and venous thrombosis, and combination effects with other antithrombotic agents. J Thromb Haemost [XXth ISTH Congress (Aug 6-12) 2005] 2005, 3(1): Abst P0511.
26. Morishima, Y., Furugohri, T., Isobe, K. et al. DU-176b, an oral and direct factor Xa inhibitor: In vitro pharmacological profile, pharmacodynamics, and antithrombotic effects. J Pharmacol Sci 2006, 100(1): 168P.
27. Morishima, Y., Furugohri, T., Isobe, K. et al. In Vitro Characteristics, Anticoagulant effects and in vivo antithrombotic efficacy of a novel, potent and orally active direct factor Xa inhibitor, DU-176b. 46th Am Soc Hematol (Dec 4-7, San Diego) 2004, Abst 1862.
28. Fukuda, T., Matsumoto, C., Honda, Y., Morishima, Y., Shibano, T. Antithrombotic effects of a direct factor Xa inhibitor, DU-176b, and an antithrombin dependent factor Xa inhibitor, fondaparinux, on an ex vivo capillary perfusion chamber thrombosis model in rats. J Thromb Haemost [XXth ISTH Congress (Aug 6-12) 2005] 2005, 3(1): Abst P0612.
29. Shibano, T., Tsuji, N., Fukuda, T., Morishima, Y. Comparison of antithrombotic properties of a direct FXa inhibitor, DU-176b, with an antithrombin dependent FXa inhibitor, fondaparinux, in a capillary perfusion chamber thrombosis model. J Thromb Haemost [XXIst ISTH Congress (July 31 -Aug 4) 2007] 2007, 5(1): Abst P-T-640.
30. Furugohri, T., Honda, Y., Matsumoto, C., Isobe, K., Sugiyama, N., Morishima, Y., Shibano, T. Antithrombotic and hemorrhagic effects of DU-176b, a novel, potent and orally active direct factor Xo inhibitor: A wider safety margin compared to heparins and warfarin. 46th Am Soc Hematol (Dec 4-7, San Diego) 2004, Abst 1851.
31. Morishima, Y., Honda, Y., Kamisato-Matsumoto, C., Shibano, T. Treatment of venous thrombosis with the oral direct factor Xa inhibitor DU-176b in conscious rats. J Thromb Haemost [XXII ISTH Congress (July 11-16) 2009] 2009, 7(2): Abst PP-TH-406.
32. Morishima, Y., Fukuda, T., Tsuji, N., Honda, Y., Matsumoto, C., Furugohri, T., Shibano, T. A thrombin inhibitor, but not a factor Xa inhibitor, DU-176b, aggravates tissue factor-induced hypercoagulation in rots. 47th Am Soc Hematol (Dec 10-14, Atlanta) 2005, Abst 1878.
33. Furugohri, T., lsobe, K., Honda, Y., Matsumoto, C., Sugiyama, N., Morishima, Y., Shibano, T. Pharmacological characterization, antithrombotic and bleeding effects of DU-176b, a novel, potent and orally active direct inhibitor of factor Xa: A wider safety margin of antithrombotic and bleeding effects compared to heparin, LMWH and warfarin. J Thromb Haemost [XXth ISTH Congress (Aug 6-12) 2005] 2005, 3(1): Abst P1110.
34. Zafar, M.U., Vorchheimer, D.A., Gaztanaga, J. et al. Antithrombotic effects of factor Xa inhibition with DU-176b: Phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber. Thromb Haemost 2007, 98(4): 883-888 (Pubitemid 47555083)
35. Mendell, J., Tachibana, S., Shi, M., Kunitada, S. Effect of food on disposition of DU-176b: Pharmacokinetic and pharmacodynamic effects in Caucasian and Japanese healthy volunteers. J Thromb Haemost [XXII ISTH Congress (July) 2009] 2009, 7(2): Abst PP-MO-198.
36. Shibano, T., Tsuji, N., Kito, F., Fukuda, T., Furugohri, T., Morishima, Y. Effects of DU-176b, a novel direct factor Xa inhibitor, on prothrombinase activity and platelet aggregation in vitro. J Thromb Haemost [XXIst ISTH Congress (July 31-Aug 4) 2007] 2007, 5(2): Abst P-T-642.
37. Morishima, Y., Shirasaki, Y., Kito, F., Honda, Y., Shibano, T. Effect of a factor Xa inhibitor DU-176b on intracerebral hemorrhage in rats: A wider safety margin compared with a thrombin inhibitor. J Thromb Haemost [XXIst ISTH Congress (July 31-Aug 4) 2007] 2007, 5(2): Abst P-T-641.
38. Morishima, Y., Honda, Y., Matsumoto, C., Fukuda, T., lsobe, K., Kumada, T., Shibano, T. Recombinant factor Vlla reverses the prolonged bleeding time induced by a high dose of DU-176b, a novel direct factor Xa inhibitor, in rats. J Thromb Haemost [XXth ISTH Congress (Aug 6-12) 2005] 2005, Abst P0512.
39. Morishima, Y., Fukuda, T., Honda, Y., Shibano, T. Activated prothrombin complex concentrate, recombinant factor VIII and factor IX reverse prolonged clotting time induced by DU-176b, a direct factor Xa inhibitor, in human plasma. J Thromb Haemost [XXIst ISTH Congress (July 31-Aug 4) 2007] 2007, 5(2): Abst P-T-639.
40. Samama, M.M., Kunitada, S., Oursin, A., Depasse, F., Haque, N. Study of Coagulation and platelets response in an open label randomised non treatment and active controlled (dalteparin, ximelagatran and DU- 176b) in 4 groups of elderly healthy subjects. 50th Am Soc Hematol (Dec 6-9, San Francisco) 2008, Abst 3026.
41. Fuji, T., Fujita, S., Tachibana, S., Kawai, Y. Randomized, Double-Blind, Multi-Dose Efficacy, safety and biomarker study of the oral factor Xa inhibitor DU-176b compared with placebo for prevention of venous thromboembolism in patients after total knee arthroplasty. 50th Am Soc Hematol (Dec 6-9, San Francisco) 2008, Abst 34.
42. Raskob, G., Cohen, A., Eriksson, B. I. et al. Randomized double-blind multi-dose trial of the oral factor-Xa inhibitor DU-176b versus LMW heparin (dalteparin) for prevention of venous thromboembolism after total hip replacement. Eur Heart J 2008, 29(1): Abst P3712.
43. Weitz, J.I., Connolly, S.J., Kunitada, S., Jin, J., Patel, I. Randomized, Parallel Croup, multicenter, multinational study evaluating safety of DU-176b compared with warfarin in subjects with non-valvular atrial fibrillation. 50th Am Soc Hematol (Dec 6-9, San Francisco) 2008, Abst 33.
44. Giugliano, R., Rohatagi, S., Kastrissios, H. et al. The relationship between oral factor Xa (FXa) inhibitor DU-176b pharmacokinetics (PK) and the probability of bleeding events (BE) in patients with atrial fibrillation (AF). J Thromb Haemost [XXII ISTH Congress (July 11-16) 2009] 2009, 7(2): Abst OC-WE-003.
45. Yasaka, M., Inoue, H., Kawai, Y. et al. Randomized, parallel group, warfarin control, multicenter phase II study evaluating safety of DU-176b in japanese subjects with non-valvular atrial fibrillation. J Thromb Haemost [XXII ISTH Congress (July 11-16) 2009] 2009, 7(2): Abst PP-WE-196.
46. Global study to assess the safety and effectiveness of DU-176b vs standard practice of dosing with warfarin in patients with atrial fibrillation (EngageAFTIMI48) (NCT00781391). ClinicalTrials.gov Web site, 30 December, 2009.
47. Mendell, J., Noveck, I., Rubets, I., Luo, R., Shi, M., Salazar, D. The factor Xa inhibitor DU-176B is safe in healthy subjects 24 h post warfarin treatment: a randomized, double-blind study. J Thromb Haemost [XXII ISTH Congress (July 11-16) 2009] 2009, 7(2): Abst PP-WE-179.